Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

导出原文传递

翻译打印收藏纠错

作者： Michael,Slade ^[1] ; Thomas G.,Martin ^[2] ; Nitya,Nathwani ^[3] ; Mark A.,Fiala ^[4] ; Michael P.,Rettig ^[5] ; Feng,Gao ^[6] ; Abhinav,Deol ^[7] ; Francis K.,Buadi ^[8] ; Jonathan L.,Kaufman ^[9] ; Craig C.,Hofmeister ; Tara K.,Gregory ; Jesus,Berdeja ; Ajai,Chari ; Ashley,Rosko ; Ravi,Vij

作者单位： Washington University School of Medicine ^[1] University of California- San Francisco ^[2] Judy and Bernard Briskin Center for Multiple Myeloma Research,City of Hope Comprehensive Cancer ^[3] Karmanos Cancer Institute,Wayne State University ^[4] Mayo Clinic ^[5] Emory University ^[6] Sarah Cannon Research Institute ^[7] Icahn School of Medicine at Mount Sinai ^[8] Ohio State University ^[9]

发布时间 2023-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia

2022年36卷12期

2917-2921页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除